Recent advances of therapeutic targets and potential drugs of COVID-19
- PMID: 32393419
- DOI: 10.1691/ph.2020.0431
Recent advances of therapeutic targets and potential drugs of COVID-19
Abstract
Since December 2019, numerous cases of coronavirus disease 2019 (COVID-19) caused by the infection of the novel coronavirus (2019-nCoV) have been confirmed in Wuhan, China. The outbreak of 2019-nCoV in China embodied a significant and urgent threat to global health. 2019-nCoV was a new, highly contagious coronavirus discovered following the outbreak of SARS coronavirus (SARS-CoV) and MERS coronavirus (MERS-CoV). The novel coronavirus can cause severe respiratory disease and even death. However, no specific therapeutic drugs have been developed clinically thus far. This article examines the potential of therapeutic drugs by assessing the structure of 2019-nCoV, its mechanism in invading host cells, and the anti-viral mechanism of the human autoimmune system. We also review the latest research regarding the progress of potential therapeutic drugs and provide references for new drug developments of COVID-19.
Similar articles
-
[Rapid establishment of traditional Chinese medicine prevention and treatment of 2019-nCoV based on clinical experience and molecular docking].Zhongguo Zhong Yao Za Zhi. 2020 Mar;45(6):1213-1218. doi: 10.19540/j.cnki.cjcmm.20200206.501. Zhongguo Zhong Yao Za Zhi. 2020. PMID: 32281327 Chinese.
-
Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV.Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1021-1026. doi: 10.1007/s10096-020-03883-y. Epub 2020 Apr 13. Eur J Clin Microbiol Infect Dis. 2020. PMID: 32285293 Free PMC article. Review.
-
Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.Curr Top Med Chem. 2020;20(16):1423-1433. doi: 10.2174/1568026620999200517043137. Curr Top Med Chem. 2020. PMID: 32416679
-
Potential therapeutic targets and promising drugs for combating SARS-CoV-2.Br J Pharmacol. 2020 Jul;177(14):3147-3161. doi: 10.1111/bph.15092. Epub 2020 Jun 5. Br J Pharmacol. 2020. PMID: 32368792 Free PMC article. Review.
-
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5. Cell. 2020. PMID: 32142651 Free PMC article.
Cited by
-
CRISPR-Based Approaches for Efficient and Accurate Detection of SARS-CoV-2.Lab Med. 2021 Mar 15;52(2):116-121. doi: 10.1093/labmed/lmaa101. Lab Med. 2021. PMID: 33316059 Free PMC article. Review.
-
SARS-CoV-2 vaccine candidates in rapid development.Hum Vaccin Immunother. 2021 Mar 4;17(3):644-653. doi: 10.1080/21645515.2020.1804777. Epub 2020 Oct 29. Hum Vaccin Immunother. 2021. PMID: 33121319 Free PMC article. Review.
-
Recent advance of ACE2 and microbiota dysfunction in COVID-19 pathogenesis.Heliyon. 2021 Jul 10;7(7):e07548. doi: 10.1016/j.heliyon.2021.e07548. eCollection 2021 Jul. Heliyon. 2021. PMID: 34296023 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous